Trial Profile

A Phase II Study of Niraparib in Combination With EGFR Inhibitor Panitumumab in Patients With Advanced Colorectal Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niraparib (Primary) ; Panitumumab (Primary)
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms NIPAVect

Most Recent Events

06 Jun 2023 Results assessing safety and efficacy of the combination of niraparib and panitumumab in patients with advanced colorectal cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
03 Jan 2023 Status changed from recruiting to active, no longer recruiting.
01 Nov 2022 Planned number of patients changed from 26 to 40.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com